SXTP Sixty Degrees Pharmaceuticals

NEUTRAL Impact: 4/10 PRESS-RELEASE
Horizon months Filed Mar 18, 2026 Processed 2mo ago Wire GlobeNewswire
Press release: regulatory
Final — all horizons settled through T+60d
SXTP ▼ -34.91% at T+60d
NEUTRAL call ✗ call lost -34.91% · α vs SPY -46.43% · entry $2.12 → $1.38
Last close $1.36 (close Jun 12) · -35.85% from $2.12 entry
Entry anchored
Mar 17, 03:59 PM ET
via Databento tick
T+1d
-8.96%
call -8.96% · α -8.70%
$1.93
settled 3mo ago
T+5d
-26.89%
call -26.89% · α -26.17%
$1.55
settled 3mo ago
T+20d
-18.40%
call -18.40% · α -24.44%
$1.73
settled 2mo ago
T+60d
-34.91%
call -34.91% · α -46.43%
$1.38
settled 3d ago

Price Chart

Loading chart...

Executive Summary

Sixty Degrees Pharmaceuticals submitted a New Dietary Ingredient Notification (NDIN) to the FDA for a dietary supplement containing Australian Chestnut Extract, with no objection period ending May 25, 2026. The company also secured an option to license a new capsule formulation from Florida State University, expanding its earlier license for large-scale purification of castanospermine.

Actionable Insight

Monitor FDA non-objection status by May 25, 2026 — a green light could enable near-term commercialization of a dietary supplement, providing early monetization of castanospermine. However, given the company's going-concern uncertainty and lack of manufacturing capacity, any commercial impact remains speculative.

Key Facts

  • Submitted NDIN to FDA for Australian Chestnut Extract on March 11, 2026
  • FDA has until May 25, 2026 to object; no objection allows marketing
  • Signed option agreement with Florida State University to license capsule formulation technology
  • Expanded on January 2026 license for large-scale purification of castanospermine
  • Castanospermine is the active constituent and has prior human safety data via celgosivir trials

Financial Impact

No immediate financial impact disclosed; potential long-term revenue if commercialized

revenueR&D pipeline

Risk Factors

  • FDA may object to the NDIN before May 25, 2026
  • Company has substantial doubt about its ability to continue as a going concern
  • No manufacturing capacity — reliant on third parties for production

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258123
4 reports for SXTP
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SXTP — sortable, filterable
Type Now
May 26, 2026
19d ago
Press Release
NEUTRAL ★ 4/10
$1.50 $1.46▼ −2.67%▼ −3.75%$1.36 (−9.33%)
May 15, 2026
4w ago
Press Release
BEARISH ★ 6/10
$1.39 $1.48▼ −6.47%▼ −5.51%$1.36 (+2.16%)
Mar 31, 2026
10w ago
Press Release
MIXED ★ 5/10
$1.75 $1.81▲ +3.43%▼ −0.52%$1.36 (−22.29%)
Mar 18, 2026
12w ago
Press Release
NEUTRAL ★ 4/10
$2.12 $1.55▼ −26.89%▼ −26.17%$1.36 (−35.85%)
Showing 4 of 4

US Market Status

Market Closed — Opens in 5h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access